Bio-Techne at LBx for Precision Oncology | February 18-20, 2025 | Hilton La Jolla Torrey Pines | San Diego, CA
Visit with us in the exhibition hall to learn how Bio-Techne can be your partner from discovery to commercialization.
Bio-Techne offers precision medicine services to pharma partners spanning the continuum from biomarker discovery to post-market commercialization of companion diagnostic (CDx) products. We take a unique, platform-agnostic approach to biomarker discovery and fit-for-purpose assay development. Our readiness for clinical trial sample testing in on-site CLIA labs, combined with diagnostic kit manufacturing and international regulatory expertise, enables us to provide customizable solutions.
Our expertise in CDx Development allows our pharma partners to enhance the likelihood of their drug's success and expedite the delivery of novel treatments to the patients who stand to benefit the most.
ESR1 & Beyond: Leveraging Exosomes for Highly Sensitive LBx Solutions
Presenter: Brian Haynes, PhD
Senior Director, Research & Development, Asuragen, a Bio-Techne Brand
- Exosomes enable more complete and sensitive disease detection than ctDNA alone with unparalleled sensitivity (<0.1%VAF) to detect ESR1 mutations on widely available instruments.
- The QuantideX® qPCR ESR1 exoMutation Kit (RUO) combines co-enrichment of ctDNA and exosomal RNA, qPCR reagents, and automated push-button software for a complete LBx solution for clinical research laboratories everywhere.
Wednesday, February 19th | 3:00 PM PST
Trusted Partner for Exosome-based Biomarker Development
Bio-Techne can:
- Get versatility in target analytes to accurately characterize and stratify patient populations
- Analyze biofluids that can provide minimally and non-invasive options to obtain critical information
- Create customized experimental approaches based on over a decade of exosome experience
- Utilize regulatory experience to ensure that the approval of your targeted therapy is paired with a cleared assay ready for clinical use
Additional Resources
Beyond cfDNA: Harnessing the Power of Exosomes for Improved Sensitivity
Blood-based liquid biopsies are making inroads in cancer management and are increasingly used in conjunction with tissue biopsies. Plasma cfDNA, ctDNA and exoRNA can be used to molecularly profile cancer patients and guide downstream treatment decisions.
Accelerating the Drug Development Journey
The QuantideX® technology can be adapted to monitor disease burden in diseases requiring highly sensitive detection and/or quantitation across multiple nucleic acid targets. It can also be utilized for designing high performing, efficient, and simplified kits for genetic targets with unmet biomarker development and clinical trial assay (CTA) needs.
New Assay Offers Sensitive, Rapid, Noninvasive Classification of Gliomas
- Robust isolation protocol allows for analysis of extracellular vesicle RNA from blood samples.
- In adults, the most common type of abnormal growth in the central nervous system is glioma.
- In this study, scientists developed a blood-based assay from which they analyzed extracellular vesicle RNA found in just 2 mL of plasma. The assay incorporates droplet digital PCR for detection of the IDH1.R132H mutation. Using EV RNA instead of DNA as a target allowed the assay to achieve sensitivity of 75% and specificity of nearly 89%. The entire workflow takes less than four hours from the time a sample is collected.
Dynamic Neuronal Exosomal Biomarkers in Cell Culture Medium
Multiple partnerships with Exosome Diagnostics, a Bio-Techne brand, highlights capabilities for exosome approaches to support characterization through cell culture of progenitor cells and differentiated cells. Studies are broadly applicable across research areas but specifically showcase capabilities of exosome RNA as dynamic biomarkers in neuronal progenitors and differentiated cells.
Meet With Us to Accelerate Your Journey!
For more information and registration details, please visit the LBx Summit website.